Firecrest Clinical has launched a mobile version of its site management and training platform, citing investigator demand for trial in your hand solutions and sponsor demand for increased research efficiency.
Catalent Pharma Solutions and German expression system developer Cevec Pharmaceuticals have partnered to create a cell development service that, they claim, will help drugmakers generate stable lines faster.
in-PharmaTechnologist.com presents its latest round up of movements in the pharma sector, including appointments at PhRMA, Dyax, Alnylam, Avi BioPharma, Pacira, Asmacure and Xceleon.
GlaxoSmithKline (GSK) is investing more than CA$30m (€21m) to add dermatology product manufacturing capabilities and create 70 jobs at a Canadian plant.
Quotient Amersham Radiochemicals has been rebranded as Quotient Custom Radiolabelling in the latest stage of two year expansion programme by parent Quotient Bioresearch.
GlaxoSmithKline (GSK) has announced plans to buy its joint venture Shenzhen GSK Neptunus Biologicals (GSKNB) to expand influenza vaccine production capacity in China.
US drugmaker Baxter International has been ordered to pay compensation of $625,000 to the estate of man who received a dose of heparin that was contaminated with over-sulfated chondroitin sulphate (OSCS).
Brussels should step in to break the decade-long deadlock over the setting up of a mandatory registry for nanomaterial-containing products, said the European Trade Union Institute (ETUI).
Canadian lab services contractor Warnex posted improved results for Q1 with gains made by its bioanalytical unit offsetting a decline in its analytical services business.
Symetic has opened a new lab facility to showcase its range of processing systems to the pharmaceutical manufacturing, packaging and nutraceutical sectors.
Indian contract research organisation (CRO) GVK Biosciences has signed a deal allowing pharmaceutical researchers across the US to access its clinical biomarker database.
The fall in the number of trials conducted in Russia in Q1 is a ‘temporary blip’ says Synergy Research Group general manager Igor Stefanov, who cites recent changes to the approval process, rather than a drop in demand, as the key factor.
Pfizer has begun what it claims is the world’s first ‘virtual’ trial and says that such innovation is needed to make sure clinical research is sustainable.
Switzerland-based life sciences supplier Lonza says it will invest CHF10m (€8m) to expand a Singapore plant that is part of its custom biomanufacturing business.
Indian drugmakers Serum Institute and Panacea Biotech have reduced what they charge the GAVI for vaccines, prompting similar commitments from several Big Pharma firm.
UK drug major GSK has entered into a ‘strategic partnership’ with MaRS Innovation, a Canadian group focused on harnessing the commercial potential of the discovery pipelines of 16 top Toronto academic institutions in its network.
Indian CRAMS firm Jubilant Life Sciences has renamed HollisterStier Contract Manufacturing and hired a new BD exec in latest stage of North American reorganisation.
Ashland will buy International Specialty Products (ISP) in a deal designed to expand it's business in less cyclical, high-growth markets such as pharmaceuticals and personal care.
